AbbVie (ABBV) | Stock Overview & Key Data
AbbVie Performance Comparison
Stock Range
Today's Range
Low: $197.14
High: $200.33
on August 8, 2025
52 Week Range
Low: $163.81
High: $218.66
on November 19, 2024
on March 10, 2025
All-Time High: $218.66 on March 10, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$349.4B
EPS
2.10
P/E Ratio (TTM)
94.17
Forward P/E
16.30
P/B Ratio
-2,553.99
PEG Ratio
16.30
Div. Yield
3.44%
ROE
112.85%
Beta
0.503
Debt to Equity
-511.49
Financial Highlights
Profitability
Gross Margin
71.82%
Operating Margin
37.52%
Profit Margin
6.45%
Returns and Earnings
Return on Assets (TTM)
8.87%
Return on Equity (TTM)
112.85%
EBITDA
$16.9B
Net Income (TTM)
$3.7B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$33.04
Quarterly Revenue Growth (YoY)
6.60%
Quarterly Earnings Growth (YoY)
-31.50%
Dividend Information
Last 12-Month Dividend
$6.38
Current Dividend Yield
3.44%
3-Year Average Dividend Yield
0.95%
3-Year Average Annual Dividend
$6.07
3-Year Total Dividends
$18.22
Ex-Dividend Date
April 15, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| AbbVie ABBV | 349.35B Mega-cap | 5.21% | 5.99% | 5.73% | 4.33% | 10.82% | 4.72% | 39.48% | 109.21% |
| Eli Lilly and LLY | 687.24B Mega-cap | -13.41% | -17.08% | -17.49% | -27.03% | -17.63% | -16.30% | 142.26% | 397.28% |
| Johnson & Johnson JNJ | 411.92B Mega-cap | 4.12% | 10.47% | 9.05% | 12.02% | 19.10% | 6.21% | 3.20% | 15.08% |
| Merck & Co MRK | 200.53B Mega-cap | 2.88% | -0.66% | 1.58% | -7.92% | -18.96% | -30.65% | -12.72% | -0.28% |
| Amgen AMGN | 153.26B Large-cap | -3.52% | -2.82% | 3.21% | -3.01% | 9.80% | -11.73% | 14.60% | 18.75% |
| Gilead Sciences GILD | 142.44B Large-cap | -1.79% | -1.34% | 11.51% | 14.83% | 20.03% | 49.71% | 75.16% | 60.99% |
Ownership & Short Interest
Insider Ownership
0.11%
Institutional Ownership
74.85%
Shares Short
16M
Short Ratio
2.23
Short % of Shares Outstanding
0.88%
Average 10-Day Volume
5M
Average 90-Day Volume
6M
AbbVie Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in AbbVie would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ABBV's 52-week high and low?
- In the last 52 weeks, AbbVie reached a high of $218.66 (on March 10, 2025) and a low of $163.81 (on November 19, 2024).
- What is the market cap and P/E ratio for ABBV?
- Curious about AbbVie's size and valuation? Its market capitalization stands at 349.35B. When it comes to valuation, the P/E ratio (trailing twelve months) is 94.17, and the forward P/E (looking ahead) is 16.30.
- Does ABBV pay dividends? If so, what's the yield?
- Yes, AbbVie is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 3.44%, and the company has paid an average of $6.07 per share annually over the past 3 years.
- Who are AbbVie's main competitors or similar companies to consider before investing?
When looking at AbbVie, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Eli Lilly and
LLY687.24B Healthcare Drug Manufacturers - General -16.30% 142.26% Johnson & Johnson
JNJ411.92B Healthcare Drug Manufacturers - General 6.21% 3.20% Merck & Co
MRK200.53B Healthcare Drug Manufacturers - General -30.65% -12.72% Amgen
AMGN153.26B Healthcare Drug Manufacturers - General -11.73% 14.60% Gilead Sciences
GILD142.44B Healthcare Drug Manufacturers - General 49.71% 75.16% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for AbbVie Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of AbbVie's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 112.85%, the Debt to Equity ratio from the most recent quarter is -511.49, and its Gross Profit Margin stands at 71.82%.
- What is the recent revenue and earnings growth for ABBV?
- Looking at AbbVie's growth, its revenue over the trailing twelve months (TTM) was $58B. Compared to the same quarter last year (YoY), quarterly revenue grew by 6.60%, and quarterly earnings saw a YoY growth of -31.50%.
- How much of ABBV stock is held by insiders and institutions?
- Wondering who owns AbbVie stock? Company insiders (like executives and directors) hold about 0.11% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 74.85%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.